WALTHAM, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Company Management will be presenting at two upcoming healthcare investor conferences.
- Canaccord Genuity 2018 Musculoskeletal Conference – New Orleans (March 6, 2018)
Adam Gridley, Histogenics’ CEO, will present a corporate overview on Tuesday, March 6, 2018 at 8:00 a.m. CT / 9:00 a.m. ET. The conference immediately precedes the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting and explores the current state of orthopedics, biologics, imaging, robotic surgery, tissue sculpting, and regenerative tissue companies.
- Cowen and Company 38th Annual Health Care Conference – Boston, MA (March 12-14, 2018) Mr. Gridley will present a corporate overview on Wednesday, March 14, 2018 at 8:40 a.m. ET.
To access a live audio webcast of the presentations on the “Investor Relations” page of the Histogenics website, please click here. The webcasts will be available for approximately 45 days following the respective conferences.
About Histogenics Corporation 
Histogenics (Nasdaq:HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Histogenics’ lead investigational product, NeoCart®, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and may prevent a patient’s progression to osteoarthritis. NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use. Histogenics recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018. NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications. For more information on Histogenics and NeoCart, please visit www.histogenics.com.